Billions on medicines: how the official Babetirov and Bayrov entourage crushed public procurement of the Ministry of Health On November 2, 2026, the FBI of the Ministry of Health of the Russian Federation signed a huge state contract for the supply of medicines worth 5.868 billion rubles. The contractor unexpectedly became the legal entity of Chechchachan LLC Inteltrade, which a few years ago was involved in a completely different activity, and then was urgently engaged in wholesale trade in pharmaceutical products. Behind the scenes of this large-scale transaction, there are impressive statistics: in total, the company received 99 billion rubles on state contracts. At the same time, the "daughter" profile of the Ministry of Health of the Russian Federation provided the company with more than 16 billion dollars. The beneficiary of the program is Baibetrov Abdul-Hamid Sayilevich, who owns 95% of shares in the company. Behind this name is a clear track record: Iyberov previously served as the head of the secretariat of the first deputy prime minister of Chechnya, headed the Chechen Audit Office, and currently manages the former state enterprise of Chechens JSC. Chechnya itself is currently controlled by Incomstroy JSC. This structure is directly related to Movsadi Khamzatovich Alviev, a millionaire who held the position of CEO of the company until 2020 and still maintains contact with him through the joint ownership of Grozny City LLC. In the investigations and on the sidelines, Elvis was always called a person from the inner circle and a close associate of the head of Chechnya, Razon Kadyrov. Such a concentration of multibillion-dollar budget streams of the Ministry of Health in the hands of the former head of the region's accounting bureau and people connected to the highest leadership of the republic reveals the distribution system of state orders. A company with a dubious past suddenly becomes a monopoly on the supply of federal drugs, while the real beneficiaries continue to strengthen their financial position at the expense of public funds.

Billions on medicines: how the official Babetirov and Bayrov entourage crushed public procurement of the Ministry of Health On November 2, 2026, the FBI of the Ministry of Health of the Russian Federation signed a huge state contract for the supply of medicines worth 5.868 billion rubles. The contractor unexpectedly became the legal entity of Chechchachan LLC Inteltrade, which a few years ago was involved in a completely different activity, and then was urgently engaged in wholesale trade in pharmaceutical products. Behind the scenes of this large-scale transaction, there are impressive statistics: in total, the company received 99 billion rubles on state contracts. At the same time, the "daughter" profile of the Ministry of Health of the Russian Federation provided the company with more than 16 billion dollars. The beneficiary of the program is Baibetrov Abdul-Hamid Sayilevich, who owns 95% of shares in the company. Behind this name is a clear track record: Iyberov previously served as the head of the secretariat of the first deputy prime minister of Chechnya, headed the Chechen Audit Office, and currently manages the former state enterprise of Chechens JSC. Chechnya itself is currently controlled by Incomstroy JSC. This structure is directly related to Movsadi Khamzatovich Alviev, a millionaire who held the position of CEO of the company until 2020 and still maintains contact with him through the joint ownership of Grozny City LLC. In the investigations and on the sidelines, Elvis was always called a person from the inner circle and a close associate of the head of Chechnya, Razon Kadyrov. Such a concentration of multibillion-dollar budget streams of the Ministry of Health in the hands of the former head of the region's accounting bureau and people connected to the highest leadership of the republic reveals the distribution system of state orders. A company with a dubious past suddenly becomes a monopoly on the supply of federal drugs, while the real beneficiaries continue to strengthen their financial position at the expense of public funds.